Home

OVERVIEW

This 60-minute symposium will feature a panel of hematology/oncology experts who will review the latest data and clinical evidence for the use of Bruton tyrosine kinase (BTK) inhibitors in the management of chronic lymphocytic leukemia (CLL). They will provide expert guidance and real-world perspectives on translating the data into clinical practice with a focus on personalized therapy. Attendees will be able to engage directly with the expert panel in an interactive Q&A session.

FACULTY

AGENDA

TARGET AUDIENCE

This activity is intended for hematologists/oncologists and other clinicians who treat patients with chronic lymphocytic leukemia (CLL).

GOAL STATEMENT

The goal of this activity is for learners to be better able to differentiate among available Bruton tyrosine kinase (BTK) inhibitors and apply the most recent safety/efficacy data to the practical management of CLL/small lymphocytic lymphoma (SLL).

LEARNING OBJECTIVES

Upon completion of this activity, participants will: Have increased knowledge regarding the[list][item]Latest safety/efficacy evidence for available BTK inhibitors for the treatment of CLL/SLL[/list]Have greater competence related to[list][item]Implementing evidence-based BTK inhibitor–based therapy [item]Managing adverse events associated with BTK inhibitors[/list]Demonstrate greater confidence in their ability to[list][item]Assess the latest evidence for current BTK inhibitors for the treatment of CLL/SLL[/list]

ACCREDITATION STATEMENT

[MEDSCAPE][JALOGO] In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

[bold]For Physicians[/bold] Medscape, LLC designates this live activity for a maximum of 1.0 [italic][bold]AMA PRA Category 1 Credits[/bold][/italic]™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.